$6.78
0.89%Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.
Quality against peers; 50 is the peer median.
No reported financials for this company yet: it has too few SEC filings to chart.
The latest fiscal year and quarter, each against the same period a year earlier, from SEC filings.
The next report, and the record against analysts' estimates.
Fundamentals: trailing twelve months to Jun 2026, from the latest 10-K and 10-Qs.
IM industry median · SM sector median: the typical company the value is compared with. The /100 is its score against those peers.
The companies closest in size in Biotechnology (filled from its sector when there are few), with the median and rank across all 571 in the industry.